Pharmacological reports : PR最新文献

{"title":"The effect of poly I:C or LPS priming on the therapeutic efficacy of mesenchymal stem cells in an adjuvant-induced arthritis rat model.","authors":"Samira Zolfaghari, Peiman Brouki Milan, Ahmad Reza Dehpour, Motahareh Rajabi Fomeshi, Fatemeh Eskandari, Loghman Ebrahimi, Seyed Mahmoud Hashemi, Mohammad Taghi Joghataei","doi":"10.1007/s43440-022-00386-9","DOIUrl":"10.1007/s43440-022-00386-9","url":null,"abstract":"<p><strong>Background: </strong>The immunomodulatory properties of mesenchymal stem cells (MSCs) have made them a prospective treatment option for inflammatory and autoimmune disorders. Recent studies have found an association between the immunomodulatory function of MSCs and Toll-like receptors (TLRs). Here, we investigated the effect of priming with lipopolysaccharide (LPS) as TLR4 ligand or polyinosinic:polycytidylic acid (poly I:C) as TLR3 ligand on the immunomodulatory function of adipose-derived MSCs (ADMSCs) in vitro and for the first time in an adjuvant-induced arthritis model (AIA).</p><p><strong>Methods: </strong>ADMSCs were treated with LPS or poly I:C for 1 h. Splenocyte proliferation in the presence of primed ADMSCs was assessed in vitro using an MTT assay. Next, we investigated the therapeutic effect of primed ADMSCs in vivo. Male Wistar rats were infused with complete Freund's adjuvant (CFA) to develop arthritis and then intraperitoneally treated with not-primed, poly I:C- or LPS-primed ADMSCs. Clinical signs, histopathological alteration, and serum and spleen cytokine levels were analyzed.</p><p><strong>Results: </strong>Poly I:C-primed ADMSCs significantly reduced splenocytes proliferation, while ADMSCs primed with LPS increased splenocytes proliferation. Furthermore, poly I:C-primed ADMSCs significantly alleviated the clinical and histopathological severity and the secretion of inflammatory cytokines associated with Th17/Th1 such as IL-17 and IFN-γ. Poly I:C-primed ADMSCs also increased cytokines IL-10 and TGF-β. TNF-α and IL-6 Levels were also markedly diminished in the serum of AIA animals treated with poly I:C-primed ADMSCs. In contrast, priming ADMSCs with LPS significantly reduced the therapeutic effect of ADMSCs in AIA animals.</p><p><strong>Conclusion: </strong>As a result of these findings, poly I:C priming may be a new technique for improving the therapeutic effects of MSCs in arthritic disorders.</p>","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"654-668"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40599287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suppression of nitric oxide synthase aggravates non-alcoholic steatohepatitis and atherosclerosis in SHRSP5/Dmcr rat via acceleration of abnormal lipid metabolism.","authors":"Ikumi Sato,&nbsp;Shusei Yamamoto,&nbsp;Mai Kakimoto,&nbsp;Moe Fujii,&nbsp;Koki Honma,&nbsp;Shota Kumazaki,&nbsp;Mami Matsui,&nbsp;Hinako Nakayama,&nbsp;Sora Kirihara,&nbsp;Shang Ran,&nbsp;Shinichi Usui,&nbsp;Ryoko Shinohata,&nbsp;Kazuya Kitamori,&nbsp;Satoshi Hirohata,&nbsp;Shogo Watanabe","doi":"10.1007/s43440-022-00380-1","DOIUrl":"https://doi.org/10.1007/s43440-022-00380-1","url":null,"abstract":"<p><strong>Background: </strong>Non-alcoholic steatohepatitis (NASH) is a progressive subtype of non-alcoholic fatty liver disease (NAFLD) that is closely related to cardiovascular disease (CVD). Nitric oxide (NO) plays a critical role in the control of various biological processes. Dysfunction of the NO signaling pathway is associated with various diseases such as atherosclerosis, vascular inflammatory disease, and diabetes. Recently, it has been reported that NO is related to lipid and cholesterol metabolism. Chronic NO synthase (NOS) inhibition accelerates NAFLD by increasing hepatic lipid deposition. However, the detailed relationship between NO and abnormal lipid and cholesterol metabolism in NAFLD/NASH has not been completely explained. We aimed to determine the effects of NOS inhibition by N omega-nitro-L-arginine methyl ester hydrochloride (L-NAME), a NOS inhibitor, on NASH and CVD via lipid and cholesterol metabolism.</p><p><strong>Methods: </strong>Stroke-prone spontaneously hypertensive rats were fed a high-fat and high-cholesterol diet for 8 weeks and administered L-NAME for the last 2 weeks. Following blood and tissue sampling, biochemical analysis, histopathological staining, quantitative RT-PCR analysis, and western blotting were performed.</p><p><strong>Results: </strong>L-NAME markedly increased hepatic triglyceride (TG) and cholesterol levels by promoting TG synthesis and cholesterol absorption from the diet. L-NAME increased the mRNA levels of inflammatory markers and fibrotic areas in the liver. Cholesterol secretion from the liver was promoted in rats administered L-NAME, which increased serum cholesterol. L-NAME significantly increased the level of oxidative stress marker and lipid deposition in the arteries.</p><p><strong>Conclusions: </strong>NOS inhibition simultaneously aggravates NASH and atherosclerosis via hepatic lipid and cholesterol metabolism.</p>","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"669-683"},"PeriodicalIF":4.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40596020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GSK-3β-mediated regulation of Nrf2/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders.","authors":"Divya Soni, Puneet Kumar","doi":"10.1007/s43440-022-00390-z","DOIUrl":"10.1007/s43440-022-00390-z","url":null,"abstract":"<p><p>Movement disorders are neurological conditions characterized by involuntary motor movements, such as dystonia, ataxia, chorea myoclonus, tremors, Huntington's disease (HD), and Parkinson's disease (PD). It is classified into two categories: hypokinetic and hyperkinetic movements. Globally, movement disorders are a major cause of death. The pathophysiological process is initiated by excessive ROS generation, mitochondrial dysfunction, neuroinflammation, and neurotransmitters imbalance that lead to motor dysfunction in PD and HD patients. Several endogenous targets including Nrf2 maintain oxidative balance in the body. Activation of Nrf2 signaling is regulated by the enzyme glycogen synthase kinase (GSK-3β). In the cytoplasm, inhibition of GSK-3β regulates cellular proliferation, homeostasis, and apoptotic process by stimulating the nuclear factor erythroid 2 (Nrf2) pathway which is involved in the elevation of the cellular antioxidant enzymes which controls the ROS generation. The activation of Nrf2 increases the expression of antioxidant response elements (ARE), such as (Hemeoxygenase-1) HO-1, which decreases excessive cellular stress, mitochondrial dysfunction, apoptosis, and neuronal degeneration, which is the major cause of motor dysfunction. The present review explores the GSK-3β-mediated neuroprotection in various movement disorders through the Nrf2/HO-1 antioxidant pathway. This review provides a link between GSK-3β and the Nrf2/HO-1 signaling pathway in the treatment of PD and HD. In addition to that it highlights various GSK-3β inhibitors and the Nrf2/HO-1 activators, which exert robust neuroprotection against motor disorders. Therefore, the present review will help in the discovery of new therapy for PD and HD patients.</p>","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"557-569"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40636564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-micronized and micronized curcumin do not prevent the behavioral and neurochemical effects induced by acute stress in zebrafish.","authors":"Adrieli Sachett,&nbsp;Matheus Gallas-Lopes,&nbsp;Radharani Benvenutti,&nbsp;Matheus Marcon,&nbsp;Amanda M Linazzi,&nbsp;Gean P S Aguiar,&nbsp;Ana P Herrmann,&nbsp;J Vladimir Oliveira,&nbsp;Anna M Siebel,&nbsp;Angelo Piato","doi":"10.1007/s43440-022-00389-6","DOIUrl":"https://doi.org/10.1007/s43440-022-00389-6","url":null,"abstract":"<p><strong>Background: </strong>Curcumin, a polyphenol extracted from the rhizome of Curcuma longa L. (Zingiberaceae), presents neuroprotective properties and can modulate neuronal pathways related to mental disorders. However, curcumin has low bioavailability, which can compromise its use. The micronization process can reduce mean particle diameter and improve this compound's bioavailability and therapeutic potential.</p><p><strong>Methods: </strong>We compared the behavioral (open tank test, OTT) and neurochemical (thiobarbituric acid reactive substances (TBARS) and non-protein thiols (NPSH) levels) effects of non-micronized curcumin (CUR, 10 mg/kg, ip) and micronized curcumin (MC, 10 mg/kg, ip) in adult zebrafish subjected to a 90-min acute restraint stress (ARS) protocol.</p><p><strong>Results: </strong>ARS increased the time spent in the central area and the number of crossings and decreased the immobility time of the animals in the OTT. These results suggest an increase in locomotor activity and a decrease in thigmotaxis behavior. Both CUR and MC were not able to prevent these effects. Furthermore, ARS also induced oxidative damage by increasing TBARS and decreasing NPSH levels. Both CUR and MC did not prevent these effects.</p><p><strong>Conclusion: </strong>ARS-induced behavioral and biochemical effects were not blocked by any curcumin preparation. Therefore, we conclude that curcumin does not have acute anti-stress effects in zebrafish.</p>","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"736-744"},"PeriodicalIF":4.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40616970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the effects of the mGlu_2/3 antagonist LY341495 on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset.","authors":"Stephen G Nuara,&nbsp;Jim C Gourdon,&nbsp;Philippe Huot","doi":"10.1007/s43440-022-00378-9","DOIUrl":"https://doi.org/10.1007/s43440-022-00378-9","url":null,"abstract":"<p><strong>Background: </strong>We have previously demonstrated that the metabotropic glutamate 2 and 3 (mGlu_2/3) antagonist LY341495 reverses the anti-dyskinetic and anti-psychotic benefits conferred by mGlu₂ activation and serotonin 2A (5-HT_2A) antagonism. Here, we hypothesised that a higher dose of LY341495, associated with a higher antagonistic effect at mGlu₃ receptors, would result in a reduction of the reversal of mGlu₂ activation and 5-HT_2A blockade on dyskinesia, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset.</p><p><strong>Methods: </strong>After induction of parkinsonism with MPTP, marmosets entered 3 streams of experiments, in which the following treatments were administered, in combination with l-3,4-dihydroxyphenylalanine (L-DOPA), after which dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism were rated: 1. vehicle/vehicle, LY354740 (mGlu_2/3 orthosteric agonist)/vehicle, LY354740/LY341495 1 mg/kg and LY354740/LY341495 3 mg/kg; 2. vehicle/vehicle, LY487379 (mGlu₂ positive allosteric modulator)/vehicle, LY487379/LY341495 1 mg/kg and LY487379/LY341495 3 mg/kg; 3. vehicle/vehicle, EMD-281,014 (5-HT_2A antagonist)/vehicle, EMD-281,014/LY341495 1 mg/kg and EMD-281,014/LY341495 3 mg/kg.</p><p><strong>Results: </strong>Each of LY354740, LY487379 and EMD-281,014 reduced the severity of L-DOPA-induced dyskinesia, by 55%, 39% and 40%, respectively (all p < 0.001), as well as the severity of PLBs, by 48%, 36% and 41%, respectively (all p < 0.001). Adding LY341495 1 and 3 mg/kg to each of LY354740, LY487379 and EMD-281,014 resulted in a dose-dependent reversal of their anti-dyskinetic and anti-psychotic actions. No effect on the anti-parkinsonian action of L-DOPA was noted with any treatment combination.</p><p><strong>Conclusion: </strong>These results suggest that an antagonistic effect at mGlu₃ receptors may not be sufficient to overcome the deleterious effect of mGlu₂ blockade on dyskinesia in PD. It remains to be seen whether similar effects would have been obtained with a selective mGlu₃ antagonist.</p>","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"614-625"},"PeriodicalIF":4.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40400874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note to: Insights from diversified anti-angiogenic models: role of β-interferon inducer DEAE-Dextran.","authors":"Anita K Bakrania,&nbsp;Bhavesh C Variya,&nbsp;Snehal S Patel","doi":"10.1007/s43440-022-00385-w","DOIUrl":"https://doi.org/10.1007/s43440-022-00385-w","url":null,"abstract":"","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"770"},"PeriodicalIF":4.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40566641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of chronic exposure to metformin in a new type-2 diabetic NONcNZO10/LtJ mouse model of stroke.","authors":"Rashmi Kumari,&nbsp;Lisa Willing,&nbsp;Scot R Kimball,&nbsp;Ian A Simpson","doi":"10.1007/s43440-022-00382-z","DOIUrl":"https://doi.org/10.1007/s43440-022-00382-z","url":null,"abstract":"<p><strong>Background: </strong>Diabetes is an independent risk factor of stroke and previous studies have confirmed that diabetic patients and animals experience poorer clinical outcomes following stroke. In this study, we aim to determine the effect of chronic exposure of the first-line antidiabetic agent, metformin, to restore euglycemia and to impact brain cell death following stroke in a new type-2 diabetes, NONcNZO10/LtJ (RCS-10) mouse model of stroke.</p><p><strong>Methods: </strong>Male RCS-10 mice received a moderate (11%) fat diet post-weaning, at 4 weeks of age, and became diabetic by 12-14 weeks, thus resembling human maturity-onset diabetes. The mice received either metformin or vehicle for 4 weeks before undergoing a hypoxic/ischemic (HI) insult. Blood samples were collected pre-, post-treatment, and post HI for glucose and lipid measurements, and brains were analyzed for infarct size, glial activation, neuronal cell death, and metformin-mediated adenosine monophosphate-activated protein kinase (AMPK) signaling at 48 h post HI.</p><p><strong>Results: </strong>Pretreatment with metformin maintained euglycemia for 4 weeks but did not change body weight or lipid profile. Metformin treatment significantly enhanced the microglial Bfl-1 mRNA expression and showed a non-significant increase in GFAP mRNA, however, GFAP protein levels were reduced. Metformin treatment slightly increased neuronal NeuN and MAP-2 protein levels and significantly reduced overall mortality post HI but did not elicit any significant change in infarct size.</p><p><strong>Conclusion: </strong>The study suggests that the prolonged effect of metformin-induced euglycemia promoted the microglial activation, reduced neuronal cell death, and improved the overall survival following stroke, without any change in infarct size.</p>","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"696-708"},"PeriodicalIF":4.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40575263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiosensitizing effect of dendrosomal nanoformulation of curcumin on cancer cells.","authors":"Tahereh Jalali Varnamkhasti,&nbsp;Meisam Jafarzadeh,&nbsp;Majid Sadeghizadeh,&nbsp;Mahdi Aghili","doi":"10.1007/s43440-022-00383-y","DOIUrl":"https://doi.org/10.1007/s43440-022-00383-y","url":null,"abstract":"<p><strong>Background: </strong>Curcumin was found to possess numerous pharmacological activities in clinical research, however, its biological effects together with radiation are yet to be addressed. The present study investigated whether the combined treatment of dendrosomal nanoformulation of curcumin (DNC) and gamma radiation can enhance the radiosensitivity of U87MG and MDA-MB-231 cell lines.</p><p><strong>Methods: </strong>U87MG and MDA-MB-231 cell lines were exposed to 2 Gray (Gy) and 10 μM DNC determined by MTT assay, then subjected to clonogenic assay, cell cycle assay, and flow cytometric apoptosis analysis. Acridine Orange/Ethidium Bromide (AO/EB) and 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) stained cells were used to study morphologic changes. The expression evaluation of putative cell cycle genes, i.e., P53, P21, CCND1, and CCNB1 was carried out by RT-qPCR.</p><p><strong>Results: </strong>Our findings indicated that the combined treatment with DNC and radiation might cooperatively augment the efficacy of ionizing radiation in the cancer cells and notably decrease the survival and viability of the cells in a time- and concentration-dependent manner. In addition to a synergistic effect deducted by sensitizer enhancement ratio (SER) assessment, co-treatment resulted in greater apoptotic cells than the individual treatments. Further experiments then indicated that DNC could effectively induce G2/M phase cell cycle arrest and apoptosis following irradiation. Conformably, there was a decrement of CCND1 and CCNB1 expression, and an increment of P53, P21 expression.</p><p><strong>Conclusions: </strong>The data implied that DNC as a radiosensitizer can enhance the lethal effect of ionizing radiation on cancer cells which could be a promising adjuvant therapy in clinical treatments.</p>","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"718-735"},"PeriodicalIF":4.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40596021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro antiviral activity of piperidine alkaloids from Senna spectabilis flowers on Chikungunya virus infection.","authors":"Thamires Rodrigues Freitas,&nbsp;Raul Marques Novais,&nbsp;Igor Andrade Santos,&nbsp;Daniel Oliveira Silva Martins,&nbsp;Amanda Danuello,&nbsp;Vanderlan da Silva Bolzani,&nbsp;Ana Carolina Gomes Jardim,&nbsp;Marcos Pivatto","doi":"10.1007/s43440-022-00381-0","DOIUrl":"https://doi.org/10.1007/s43440-022-00381-0","url":null,"abstract":"<p><strong>Background: </strong>Chikungunya fever is an endemic disease caused by the Chikungunya virus (CHIKV). To date there is no antiviral treatment against this infection or licensed vaccine to prevent it. Our study aims to evaluate whether (-)-cassine (1) and (-)-spectaline (2), the main alkaloids of Senna spectabilis, display anti-CHIKV activity. Both compounds have been described to be biologically active against neglected tropical diseases, including malaria, leishmaniasis, and schistosomiasis, which emphasizes that these molecules could be repurposed for chikungunya fever treatment.</p><p><strong>Methods: </strong>The structures of the isolated compounds 1 and 2 were identified by NMR and HRESIMS analyses, and their antiviral activity against CHIKV was assessed by a dose-response assay employing BHK-21 cells and CHIKV-nanoluc, a recombinant virus carrying the nanoluciferase gene reporter.</p><p><strong>Results: </strong>Compound 1 presented CC₅₀ of 126.5 µM and EC₅₀ of 14.9 µM, while compound 2 presented CC₅₀ of 91.9 µM and EC₅₀ of 8.3 µM. The calculated selectivity index (SI) was 8.5 for 1 and 11.3 for 2.</p><p><strong>Conclusion: </strong>The data presented herein show that compounds 1 and 2 have potential for being repurposed as anti-CHIKV drug. Our promising in vitro results encourage further in vitro and in vivo assays. This is the first description of the antiviral activity of compounds 1 and 2 against CHIKV infection, which can impact the development of antiviral drug candidates against chikungunya fever, which sometimes can be debilitating.</p>","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"752-758"},"PeriodicalIF":4.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40636563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Radiosensitizing effect of dendrosomal nanoformulation of curcumin on cancer cells.","authors":"Tahereh Jalali Varnamkhasti,&nbsp;Meisam Jafarzadeh,&nbsp;Majid Sadeghizadeh,&nbsp;Mahdi Aghili","doi":"10.1007/s43440-022-00392-x","DOIUrl":"https://doi.org/10.1007/s43440-022-00392-x","url":null,"abstract":"","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":" ","pages":"769"},"PeriodicalIF":4.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40532079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}